Division of Sanofi
Latest From Sanofi US
Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.
US FDA heard a predictably wide range of advice on the appropriate standards for approving biosimilar and interchangeable insulin during a public hearing on the topic. What is surprising is how few sponsors decided to speak out.
In addition to fielding tough questions about pricing practices at the session, executives may announce new voluntary efforts to lower drug costs and will offer their own ideas for legislation.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
- Anne Whitaker, Pres., N. America Pharmaceuticals
- Contact Info
Phone: (800) 981-2491
55 Corporate Dr.
Bridgewater, NJ 08807
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.